Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017

GlobeNewswire June 28, 2017

Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover

GlobeNewswire June 27, 2017

Technical Research on Biotech Equities -- Celsion, Sarepta Therapeutics, BioMarin Pharma, and ContraVir Pharma

PR Newswire June 23, 2017

Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc.

Business Wire June 21, 2017

A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Existing-Home Sales Data

Benzinga.com  June 21, 2017

Sarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire June 21, 2017

Wall Street's M&A Chatter From June 9-11: Nordstrom, Sarepta, Walgreens-Rite Aid

Benzinga.com  June 12, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 31, 2017

Sarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference

GlobeNewswire May 30, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 1, 2017

Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics

Benzinga.com  April 28, 2017

Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments

GlobeNewswire April 27, 2017

Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call

Accesswire April 27, 2017

Watch These 8 Huge Call Purchases In Tuesday Trade

Benzinga.com  April 18, 2017

Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017

GlobeNewswire April 17, 2017

Research Reports Initiation on Biotech Stocks -- Sarepta Therapeutics, Galena Biopharma, Anthera Pharma, and Clovis Oncology

PR Newswire April 7, 2017

Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  April 5, 2017

Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer

GlobeNewswire April 3, 2017

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 31, 2017